State Street Corp Cellectar Biosciences, Inc. Transaction History

State Street Corp

  • $2.25 Trillion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
BUY
$3.5 - $6.9 $23,800 - $46,920
6,800 Added 4.52%
157,146 $63,000
Q3 2021

Nov 15, 2021
BUY
$8.2 - $12.4 $20,500 - $31,000
2,500 Added 1.69%
150,346 $139,000
Q2 2021

Aug 16, 2021
BUY
$11.8 - $18.2 $1.74 Million - $2.69 Million
147,846 New
147,846 $176,000

About Cellectar Biosciences, Inc.

CLRB Quotes by TradingView
  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $13M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email